On the other hand, it has been reported that the mortality rate was significantly reduced in patients receiving cisplatin-based chemotherapy with negative-ERCC1 non-small cell lung and breast tumors compared to ERCC1- positive tumors [64,69]. The gene discussed is ERCC1; the disease is breast neoplasm.